[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"budd-chiari-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:budd-chiari-syndrome":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100499384","freiburg-tips-registry-100499384",false,"NCT05782556","Freiburg TIPS Registry","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Treatment of Portal Hypertension: an Observational Study","FRETIR","Inclusion Criteria:\n\n* Patients allocated to TIPS implantation due to clinically significant cirrhotic and non-cirrhotic portal hypertension\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent","ALL","18 Years","100 Years",{"count":21,"type":22},2000,"ESTIMATED","12 Months","OBSERVATIONAL","Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial.\n\nClinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum\u002Fplasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.",[27,28,29,30,31,32],"Liver Cirrhosis","Portal Hypertension","Non-Cirrhotic Portal Hypertension","Budd Chiari Syndrome","Portal Vein Thrombosis","Portal Systemic Shunt",[34,35,29,36,37],"Liver cirhosis","Transjugular intrahepatic portosystemic shunt","Prognosis","Outcome","RECRUITING","2026-04-27",{"date":41,"type":42},"2026-05-01","ACTUAL",{"date":44,"type":42},"2023-01-01",{"date":46,"type":22},"2034-06-30",{"name":48,"class":49},"University Hospital Freiburg","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100589904","a-prospective-study-on-ivus-and-dsa-guidance-in-the-treatment-of-budd-chiari-syndrome-100589904","NCT06960473","A Prospective Study on IVUS and DSA Guidance in the Treatment of Budd-Chiari Syndrome","A Prospective Randomized Controlled Clinical Study on Interventional Treatment of Budd-Chiari Syndrome Guided by IVUS and DSA","Inclusion Criteria:\n\n* Age between 18 and 75 years.\n* Primary Budd-Chiari Syndrome (narrowing or occlusion of the inferior vena cava near the hepatic veins or hepatic vein openings).\n* Presence of membrane or short segment stenosis or occlusion suitable for balloon dilation (≤ 5 cm).\n* Child-Pugh score less than 13.\n* The patient or their authorized family member signs an informed consent form, voluntarily participating in the study and agreeing to follow-up.\n\nExclusion Criteria:\n\n* Prior interventional treatment.\n* Unfit for balloon dilation or stent placement (e.g., diffuse obstruction of the hepatic veins recommended for TIPS treatment, end-stage liver disease recommended for liver transplantation, etc.).\n* Coexisting severe heart disease (such as heart failure, severe arrhythmias), liver or kidney failure, severe infections, iodinated contrast agent allergy.\n* Coexisting hepatocellular carcinoma or other malignant tumors.\n* Pregnant or breastfeeding women.\n* Patients with a life expectancy of less than 1 year.\n* Patients unable to complete follow-up or cooperate with the study.","75 Years",{"count":60,"type":22},260,"INTERVENTIONAL",[63],"NA","This study aims to evaluate the effectiveness of interventional treatment guided by Intravascular Ultrasound (IVUS) compared to Digital Subtraction Angiography (DSA) in patients with Budd-Chiari Syndrome (BCS). Using a prospective, randomized controlled trial design, patients who meet the diagnostic criteria for BCS and are suitable for interventional treatment are randomly divided into the IVUS group and the DSA group. The IVUS group will undergo detailed assessment of vascular structure before interventional treatment to select the appropriate balloon for dilation, whereas the control group will make decisions based on DSA results. The primary endpoint of the study is the postoperative restenosis rate, while secondary endpoints include complications of interventional treatment, liver function, and patient survival rate. Successful implementation of this study will provide new technical means to optimize interventional treatment strategies for BCS, and help improve treatment outcomes and long-term prognosis for patients.",[66],"Budd-Chiari Syndrome","NOT_YET_RECRUITING","2025-04-29",{"date":70,"type":42},"2025-05-07",{"date":72,"type":22},"2025-05-18",{"date":74,"type":22},"2026-12-31",{"name":76,"class":49},"The Affiliated Hospital of Xuzhou Medical University"]